ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Glycostem Initiates Trial to Evaluate oNKord for AML
December 08, 2020Glycostem Therapeutics announced the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients. The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries. -
US FDA grants orphan drug designation to oNKord from Glycostem for multiple myeloma
October 14, 2020The designation will provide Glycostem with eligibility for seven years of market exclusivity and clear FDA guidance on specific aspects of development for rare diseases.
Pharma Sources Insight January 2025
